Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in radiopharmaceuticals and radiopharmaceutical technologies. Under the terms of the agreement, Blue Earth Diagnostics has acquired the exclusive worldwide rights to a broad family of prostate specific membrane antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer imaging, together with an exclusive option to explore therapeutic applications.

The U.S. Preventive Services Task Force (USPSTF) posted a final recommendation statement and evidence summaries on screening for prostate cancer. This final recommendation provides clinicians and their patients with important new information about the benefits and harms of prostate-specific antigen (PSA)-based screening.

May 8, 2018 — In a first, an international research team from the Department of Biopsychology at Ruhr-Universität Bochum ...

A new data analysis of the Northwestern Medicine Mobile Stroke Unit (MSU) found the specialized ambulance provided life-saving treatment 30 minutes faster than traditional transport in its first year of operation. The analysis found, on average, the MSU delivered the clot-busting drug tPA to ischemic stroke patients 52 minutes after 9-1-1 dispatch, compared to an average of 82 minutes for patients transported via ambulance.

With the support of the Austrian Science Fund FWF, researchers from Vienna have developed methods to improve functional magnetic resonance imaging (MRI) with the new generation of highly sensitive 7 Tesla (7T) scanners. These devices can create precise maps of the brain before surgery to help surgeons avoid damaging vital areas.